Veracyte Finalizes C2i Genomics Acquisition Deal
Company Announcements

Veracyte Finalizes C2i Genomics Acquisition Deal

Veracyte (VCYT) has released an update to notify the public and investors about its asset transaction finalization.

Veracyte, Inc. completed its acquisition of C2i Genomics for $70.0 million with additional future performance-based payments up to $25.0 million. The deal involves a combination of cash, escrow funds for indemnification, and shares of Veracyte stock, with a special provision for non-accredited investors. Veracyte will also register the shares for resale and has obtained a waiver to provide only selected financial statements for C2i Genomics, which will be disclosed in an upcoming report.

For further insights into VCYT financials, check out TipRanks’ Financials page.

For a comprehensive understanding of the announcement, you can read the full document here.


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles